Sign in to view content

LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration

David S. Boyer, MD

Video
Published 2025

Related

Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024

Category: Dry AMD

See more